VACBF (Nykode Therapeutics AS) Beneish M-Score: 0.00 (As of Jun. 25, 2026)


VACBF Nykode Therapeutics AS VACBF
28 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Beneish M-Score?

Nykode Therapeutics AS VACBF 28 Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 831 Biotechnology companies, Nykode Therapeutics AS ranks worse than 120336.82% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Nykode Therapeutics AS's Beneish M-Score or its related term are showing as below:

During the past 9 years, the highest Beneish M-Score of Nykode Therapeutics AS was 175.05. The lowest was -5.03. And the median was 0.35.

Nykode Therapeutics AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Beneish M-Score Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only 2.12 -5.03 175.05 -1.43 0.00

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VACBF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Beneish M-Score falls into.


VACBF
28GF Score
Nykode Therapeutics AS VACBF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Nykode Therapeutics AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $0.47 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $61.89 Mil.
Total Assets was $99.96 Mil.
Property, Plant and Equipment(Net PPE) was $5.68 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.04 Mil.
Selling, General, & Admin. Expense(SGA) was $2.43 Mil.
Total Current Liabilities was $6.19 Mil.
Long-Term Debt & Capital Lease Obligation was $1.30 Mil.
Net Income was $-12.24 Mil.
Gross Profit was $0.00 Mil.
Cash Flow from Operations was $-29.46 Mil.
 Total Receivables was $0.39 Mil.
Revenue was $8.68 Mil.
Gross Profit was $8.68 Mil.
Total Current Assets was $117.07 Mil.
Total Assets was $153.48 Mil.
Property, Plant and Equipment(Net PPE) was $7.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.25 Mil.
Selling, General, & Admin. Expense(SGA) was $4.35 Mil.
Total Current Liabilities was $9.10 Mil.
Long-Term Debt & Capital Lease Obligation was $2.15 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.471 / 0) / (0.386 / 8.679)
= / 0.044475
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8.679 / 8.679) / (0 / 0)
=1 /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (61.891 + 5.684) / 99.955) / (1 - (117.066 + 7.744) / 153.481)
=0.323946 / 0.186805
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 8.679
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.251 / (2.251 + 7.744)) / (2.039 / (2.039 + 5.684))
=0.225213 / 0.264017
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.434 / 0) / (4.345 / 8.679)
= / 0.500634
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.3 + 6.192) / 99.955) / ((2.145 + 9.099) / 153.481)
=0.074954 / 0.07326
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-12.24 - 0 - -29.456) / 99.955
=0.172238

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Nykode Therapeutics AS (VACBF) has a Beneish M-Score of 0.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nykode Therapeutics AS and its competitors. According to the industry distribution chart, Nykode Therapeutics AS ranks #999999 out of 831 companies in the Biotechnology industry.
Is Nykode Therapeutics AS's Beneish M-Score too high?
Nykode Therapeutics AS's current Beneish M-Score is 0.00. Based on the distribution chart, Nykode Therapeutics AS ranks #999999 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #999999 out of 831 companies for Beneish M-Score. This places Nykode Therapeutics AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.3% below its estimated fair value. The current Beneish M-Score is 0.00. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.3% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Beneish M-Score: 0.00
  • GF Value™: $0.76 vs. price of $0.32 (57.3% below fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score

Get the complete analysis for VACBF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value